CRMD (Cormedix) EPS (Basic) : $-0.81 (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Cormedix EPS (Basic)?

Cormedix's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.81.

Cormedix's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.81.

Cormedix's EPS without NRI for the three months ended in Sep. 2024 was $-0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.81.

During the past 3 years, the average EPS without NRI Growth Rate was -5.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Cormedix's highest 3-Year average EPS without NRI Growth Rate was 68.40% per year. The lowest was -20.80% per year. And the median was 17.50% per year.

Cormedix EPS (Basic) Historical Data

The historical data trend for Cormedix's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix EPS (Basic) Chart

Cormedix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.80

-0.77

-0.75

-0.74

-0.91

Cormedix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.17	-0.26	-0.25	-0.25	-0.05

Cormedix EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cormedix's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-46.339	-	0)	/	50.903
	=	-0.91

Cormedix's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.777	-	0)	/	58.825
	=	-0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81

Cormedix (NAS:CRMD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cormedix EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cormedix's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

19KA:Germany

Address

300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922

Website

https://www.cormedix.com

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Executives

Elizabeth Masson	officer: EVP, Head of Clinical Ops.	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Joseph Todisco	director, officer: Chief Executive Officer	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry	officer: Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Myron Kaplan	director	C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa	director	MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart	director	360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione	director	ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David	officer: EVP, Chief Financial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel	officer: EVP, Chief Commercial Officer	300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan	director	44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz	director	SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan	director	700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L.	officer: Exec VP of Tech Operations	C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Phoebe Mounts	officer: General Counsel	400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07822